Conference Coverage

Cardiac arrest in COVID-19 pandemic: ‘Survival is possible’


 

FROM AHA 2020

In-hospital cardiac arrest, March Through May 2020

The early studies of in-hospital cardiac arrest in patients with COVID-19 showed “concerningly low rates” of return of spontaneous circulation and survival, said Dr. Mitchell.

“The first was a study from Wuhan, which demonstrated a 2.9% 30-day survival and the second was a small cohort from NYC with 0% survival to hospital discharge,” he said. “This raised concerns that offering CPR to patients who had a cardiac arrest from COVID-19 might only hold a low probability of success.”

To investigate this, the researchers formed a COVID study group comprising two hospitals in New York and nine hospitals in the Northeast and West Coast.

They identified 260 hospitalized adult patients with COVID-19 who had in-hospital cardiac arrest between March 1 and May 31, 2020. The patients had a median age of 69 years, and 72% were male. Most had preexisting comorbidities. Most of the cardiac arrests were in the ICU (64%), and almost all were witnessed (91%).

Return of spontaneous circulation occurred in 22% of the patients, and 12% had survived 30 days later. Of the 260 cardiac arrests, most (204) occurred in the New York hospitals.

There was a huge variation in outcomes. The rate of sustained return of spontaneous circulation was much lower in the two hospitals in New York compared with elsewhere (11% vs. 64%), as was 30-day survival (6% vs. 36%).

“Variation in outcomes from [in-hospital cardiac arrest] has been well described prior to the COVID-19 pandemic,” said Dr. Mitchell, “and is felt to be due to a range of factors, including variation in detection and prevention of cardiac arrest, management of patients during the cardiac arrest, and differences in postarrest care – including targeted temperature management and neuroprognostication.”

“We hypothesize that the strains of the COVID-19 pandemic may have amplified these variations (although we were unable to compare hospital performance before and after the pandemic),” he said.

Nevertheless, “in contrast to [earlier] studies, we have found that survival with a good neurological status is possible after in-hospital cardiac arrest in patients with COVID-19, which is certainly reassuring for those of us on the front line.”

Dr. Chan has received research support from the American Heart Association (which helps fund CARES); the National Heart, Lung, and Blood Institute; and Optum Rx. Dr. Abella has received honoraria from NeuroproteXeon, Becton Dickinson, and Physio-Control, and research grants from Medtronic, PCORI, Physio-Control, Stryker, and TerSera. Dr. Mitchell has disclosed no relevant financial relationships.

A version of this article originally appeared on Medscape.com.

Pages

Recommended Reading

New ESC/EACTS guideline on atrial fibrillation
MDedge Emergency Medicine
RATE-AF trial boosts digoxin for rate control in permanent AFib
MDedge Emergency Medicine
HOME-PE trial clarifies which pulmonary embolism patients to treat at home
MDedge Emergency Medicine
Liberalized European sports cardiology guidelines break new ground
MDedge Emergency Medicine
‘Cautious’ DOAC underdosing in AFib may push mortality higher
MDedge Emergency Medicine
Valvular AFib heightens risk in TAVR
MDedge Emergency Medicine
AHA adds recovery, emotional support to CPR guidelines
MDedge Emergency Medicine
ACC expert consensus on post-TAVR arrhythmias
MDedge Emergency Medicine
Biometric changes on fitness trackers, smartwatches detect COVID-19
MDedge Emergency Medicine
Virtual AHA 2020 may influence template for postpandemic scientific sessions
MDedge Emergency Medicine